Toll Free: 1-888-928-9744
Published: Nov, 2015 | Pages:
107 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Klebsiella Pneumoniae Infections - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Klebsiella Pneumoniae Infections - Pipeline Review, H2 2015', provides an overview of the Klebsiella Pneumoniae Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Klebsiella Pneumoniae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Klebsiella Pneumoniae Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Klebsiella Pneumoniae Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Klebsiella Pneumoniae Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Klebsiella Pneumoniae Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Klebsiella Pneumoniae Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Klebsiella Pneumoniae Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Klebsiella Pneumoniae Infections Overview 10 Therapeutics Development 11 Pipeline Products for Klebsiella Pneumoniae Infections - Overview 11 Pipeline Products for Klebsiella Pneumoniae Infections - Comparative Analysis 12 Klebsiella Pneumoniae Infections - Therapeutics under Development by Companies 13 Klebsiella Pneumoniae Infections - Therapeutics under Investigation by Universities/Institutes 15 Klebsiella Pneumoniae Infections - Pipeline Products Glance 16 Clinical Stage Products 16 Early Stage Products 17 Klebsiella Pneumoniae Infections - Products under Development by Companies 18 Klebsiella Pneumoniae Infections - Products under Investigation by Universities/Institutes 21 Klebsiella Pneumoniae Infections - Companies Involved in Therapeutics Development 22 Arsanis Biosciences GmbH 22 Boehringer Ingelheim GmbH 23 Cellceutix Corporation 24 Debiopharm International S.A. 25 Evaxion Biotech 26 F. Hoffmann-La Roche Ltd. 27 FOB Synthesis, Inc. 28 Melinta Therapeutics, Inc 29 Merck & Co., Inc. 30 MicuRx Pharmaceuticals, Inc. 31 Nosopharm SAS 32 Novan, Inc. 33 Pfizer Inc. 34 Phico Therapeutics Limited 35 Procarta Biosystems Ltd 36 Sarepta Therapeutics, Inc. 37 Shionogi & Co., Ltd. 38 Soligenix, Inc. 39 Sumitomo Dainippon Pharma Co., Ltd. 40 Syntiron LLC 41 Tetraphase Pharmaceuticals Inc. 42 Theraclone Sciences, Inc. 43 Trana Discovery, Inc. 44 Klebsiella Pneumoniae Infections - Therapeutics Assessment 45 Assessment by Monotherapy Products 45 Assessment by Target 46 Assessment by Mechanism of Action 48 Assessment by Route of Administration 50 Assessment by Molecule Type 52 Drug Profiles 54 Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 ASN-300 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 CB-027 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 CB-618 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 CC-1807 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 CTIX-1278 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Debio-1454 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 dusquetide - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 FSI-1671 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 FSI-1686 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 GN snare - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 IBN-1 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Klebsiella pneumoniae vaccine - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Klebsiella pneumoniae vaccine - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Monoclonal Antibody for Klebsiella Pneumoniae Infections - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 MRX-V - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 NOSO-95179 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 NVN-1000 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 Onc-72 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 pneumonia vaccine - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 PT-4 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 PXS-4728A - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 RX-05 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 RXP-792 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 RXP-873 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 S-649266 - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 SM-295291 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 SM-369926 - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Small Molecule for Gram-Negative Nosocomial Infections - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 Small Molecules for Klebsiella pneumoniae Infections - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 Synthetic Peptide for Gram-Negative Bacterial Infections - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 Synthetic Peptide for Klebsiella Pneumoniae Infections - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 TP-076 - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 TP-138 - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 TP-600 - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 TP-6076 - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 Klebsiella Pneumoniae Infections - Recent Pipeline Updates 97 Klebsiella Pneumoniae Infections - Dormant Projects 103 Klebsiella Pneumoniae Infections - Discontinued Products 104 Klebsiella Pneumoniae Infections - Product Development Milestones 105 Featured News & Press Releases 105 Mar 09, 2015: Phico Therapeutics Receives Translation Award to Advance its SASPject PT4 Aimed at Escherichia coli and Klebsiella pneumoniae towards Clinical Trials 105 Sep 06, 2012: Cubist Pharma To Feature Antibiotic Drug Candidate CB-027 At ICAAC 2012 105 Appendix 106 Methodology 106 Coverage 106 Secondary Research 106 Primary Research 106 Expert Panel Validation 106 Contact Us 106 Disclaimer 107
List of Tables
Number of Products under Development for Klebsiella Pneumoniae Infections, H2 2015 11 Number of Products under Development for Klebsiella Pneumoniae Infections - Comparative Analysis, H2 2015 12 Number of Products under Development by Companies, H2 2015 14 Number of Products under Investigation by Universities/Institutes, H2 2015 15 Comparative Analysis by Clinical Stage Development, H2 2015 16 Comparative Analysis by Early Stage Development, H2 2015 17 Products under Development by Companies, H2 2015 18 Products under Development by Companies, H2 2015 (Contd..1) 19 Products under Development by Companies, H2 2015 (Contd..2) 20 Products under Investigation by Universities/Institutes, H2 2015 21 Klebsiella Pneumoniae Infections - Pipeline by Arsanis Biosciences GmbH, H2 2015 22 Klebsiella Pneumoniae Infections - Pipeline by Boehringer Ingelheim GmbH, H2 2015 23 Klebsiella Pneumoniae Infections - Pipeline by Cellceutix Corporation, H2 2015 24 Klebsiella Pneumoniae Infections - Pipeline by Debiopharm International S.A., H2 2015 25 Klebsiella Pneumoniae Infections - Pipeline by Evaxion Biotech, H2 2015 26 Klebsiella Pneumoniae Infections - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 27 Klebsiella Pneumoniae Infections - Pipeline by FOB Synthesis, Inc., H2 2015 28 Klebsiella Pneumoniae Infections - Pipeline by Melinta Therapeutics, Inc, H2 2015 29 Klebsiella Pneumoniae Infections - Pipeline by Merck & Co., Inc., H2 2015 30 Klebsiella Pneumoniae Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H2 2015 31 Klebsiella Pneumoniae Infections - Pipeline by Nosopharm SAS, H2 2015 32 Klebsiella Pneumoniae Infections - Pipeline by Novan, Inc., H2 2015 33 Klebsiella Pneumoniae Infections - Pipeline by Pfizer Inc., H2 2015 34 Klebsiella Pneumoniae Infections - Pipeline by Phico Therapeutics Limited, H2 2015 35 Klebsiella Pneumoniae Infections - Pipeline by Procarta Biosystems Ltd, H2 2015 36 Klebsiella Pneumoniae Infections - Pipeline by Sarepta Therapeutics, Inc., H2 2015 37 Klebsiella Pneumoniae Infections - Pipeline by Shionogi & Co., Ltd., H2 2015 38 Klebsiella Pneumoniae Infections - Pipeline by Soligenix, Inc., H2 2015 39 Klebsiella Pneumoniae Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 40 Klebsiella Pneumoniae Infections - Pipeline by Syntiron LLC, H2 2015 41 Klebsiella Pneumoniae Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2015 42 Klebsiella Pneumoniae Infections - Pipeline by Theraclone Sciences, Inc., H2 2015 43 Klebsiella Pneumoniae Infections - Pipeline by Trana Discovery, Inc., H2 2015 44 Assessment by Monotherapy Products, H2 2015 45 Number of Products by Stage and Target, H2 2015 47 Number of Products by Stage and Mechanism of Action, H2 2015 49 Number of Products by Stage and Route of Administration, H2 2015 51 Number of Products by Stage and Molecule Type, H2 2015 53 Klebsiella Pneumoniae Infections Therapeutics - Recent Pipeline Updates, H2 2015 97 Klebsiella Pneumoniae Infections - Dormant Projects, H2 2015 103 Klebsiella Pneumoniae Infections - Discontinued Products, H2 2015 104
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.